| CAS No. | 319460-85-0 |
|---|---|
| MDL No. | MFCD09837898 |
| MF | C22H18N4OS |
| MW | 386.50 |
| InChI Key | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Axitinib is an indazole substituted at position 3 with a 2-(pyridin-2-yl)vinyl group and at position 6 with a 2-(N-methylaminocarboxy)phenylsulfanyl group. It is used for the treatment of advanced renal cell carcinoma following failure of first-line systemic therapy. Axitinib functions as an antineoplastic agent, tyrosine kinase inhibitor, and vascular endothelial growth factor receptor antagonist. It belongs to the classes of indazoles, pyridines, aryl sulfides, and benzamides.
| CAS No. | 319460-85-0 |
|---|---|
| Product Name | Axitinib |